Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868998 · ClinicalTrials.gov registry record · Phase 2
GTX Regimen for Biliary Cancers
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00868998 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 4 participants.
The verdict
NCT00868998, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a study for patients with advanced cancer of the biliary tree, such as cholangiocarcinoma. They will be treated with a chemotherapy regimen consisting of Gemcitabine, Taxotere, and Xeloda every 21 days for at least 9 weeks. Treatment will continue until their cancer progresses. This chemotherapy regimen has been used in pancreatic cancer and there is reason to believe that it will be effective for cancers of the biliary tree as well.
Interventions
- DRUG Gemcitabine, docetaxel, and capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2005-08 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00868998
The ClinicalTrials.gov registry entry for NCT00868998 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, docetaxel, and capecitabine is the first listed.
NCT00868998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00868998 about?
NCT00868998 is a clinical study titled "GTX Regimen for Biliary Cancers". This is a study for patients with advanced cancer of the biliary tree, such as cholangiocarcinoma. They will be treated with a chemotherapy regimen consisting of Gemcitabine, Taxotere, and Xeloda every 21 days for at least 9 weeks. Treatment will continue until their cancer progresses. This chemothe...
What is the current status of trial NCT00868998?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2005-08. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00868998?
The interventions under investigation include: Gemcitabine, docetaxel, and capecitabine (DRUG).
Who is sponsoring clinical trial NCT00868998?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.